Arboviruses Slide Set

Japanese Encephalitis of Arthropod-Borne Viruses Infection

2. Japanese Encephalitis

Japanese encephalitis is a major public health problem in Asia, SE Asia, and the Indian subcontinent. Prior to 1967, thousands of cases with several hundred deaths were reported each year. In endemic areas where vector control and vaccination had been undertaken, the incidence had dropped dramatically. Epidemics had been reported from Japan, China, Korea, Taiwan, USSR, Vietnam, Philippines, ASEAN countries, India and Bangladesh. The transmission cycle in nature involve the Culex and Aedes mosquitoes and domestic animals, birds, bats, and reptiles. Man is not a preferred host for Culex mosquitoes and transmission of JE virus does not usually occur until mosquito populations are large.


Japanese encephalitis produces a high inapparent to apparent infection ratio, ranging from 25:1 to 500:1 case of encephalitis. However, when encephalitis occur, the mortality rate is in the range of 20 to 50%. Some patients will only show an undifferentiated febrile illness or have mild respiratory tract complaints. The diagnosis is usually made serologically as virus isolation is not usually successful. No specific treatment is available. An inactivated suckling mouse brain vaccine had been available since the early 1960s which had been extensively used throughout Asia. The efficacy rate ranges from 60 to 90%. Despite the vaccine being a mouse brain preparation, no postvaccination demyelinating allergic encephalitis had been reported. Mild symptoms occur in 1% of vaccinees and thus the vaccine is generally to be considered as safe.

3. Murray Valley Encephalitis

This virus is closely related to Japanese encephalitis and resembles JE clinically. It is confined to the Australia and New Guinea, where it is an important cause of epidemic encephalitis periodically. In the 8 epidemics that took place between 1917 to 1988, 330 cases were reported in Australia. The diagnosis is made by serology and no specific treatment or vaccine is available.

4. West Nile Fever

West Nile fever is a dengue-like illness that occurs in both epidemic and endemic forms in Africa, Asia, and the Mediterranean countries. Areas of high endemicity include Egypt and Iran where most of the adult population will have antibodies. West Nile virus is a member of the St Louis encephalitis complex and is transmitted by Culex mosquitoes. The virus is maintained in nature through a transmission cycle involving mosquitoes and birds. Children will usually experience an inapparent or a mild febrile illness. Adults may experience a dengue-like illness whilst the elderly may develop an encephalitis which is sometimes fatal. The diagnosis is usually made by serology although the virus can be isolated from the blood in tissue culture. No vaccine fro the virus is available and there is no specific therapy. Among the arboviruses, it is difficult to distinguish clinically between West Nile, dengue and Chikungunya. In the absence of a rash, a number of toga and bunyaviruses should also be considered in the differential diagnosis.

5. Ilheus Virus

This virus is found in Latin America where it causes a febrile illness with arthralgia. Occasionally a mild encephalitis is seen. The virus can often be confused with dengue, St Louis encephalitis, yellow fever and influenza viruses.

II. Tick-Borne Encephalitis Viruses

Tick-borne encephalitis viruses occur in temperate climates of Western and Eastern Europe and the USSR. These viruses are so closely related antigenically that it is uncertain whether to group them as separate viruses or as variants of the same virus. TBE viruses can be transmitted to a wide range of animals by ticks and is probably maintained in nature by small rodents. Humans can be infected via tick bites or by drinking milk of infected animals such as goat, cows and sheep. The clinical presentation vary from asymptomatic infection to fulminant encephalitis and death. The diagnosis is made serologically. By the time overt clinical manifestations are seen, the viraemia had already subsided so that the virus cannot be isolated from the blood or CSF. The treatment of TBE is supportive. A formalin-inactivated vaccine is available for use in the USSR which is recommended for persons living in endemic areas and for laboratory workers who may be exposed to the virus.


Louping ill is primarily a disease of sheep in England, Ireland and Scotland. Cattle, pigs, deer and some small mammals and ground-dwelling birds are also infected. It is relatively rare disease of humans caused by contact with infected tissue of sheep (butchers and vet), laboratory accidents and through tick bites. The disease caused resembles that of a mild form of tick-borne encephalitis. The disease starts of with a mild influenza-like illness which may proceed to a mild meningoencephalitis. A vaccine is available for sheep which should reduce human disease.

C. Flaviruses_Producing_Haemorrhagic_Fever


1. Yellow Fever

a. Epidemiology

Yellow fever, once a scourge of the port cities of North America and Europe, remains an important endemic and epidemic disease of Africa and South America. Yellow fever occurs in 2 major forms: urban and jungle (sylvatic) yellow fever. Jungle YF is the natural reservoir of the disease in a cycle involving nonhuman primates and forest mosquitoes. Man may become incidentally infected on venturing into jungle areas. The S American monkeys are more prone to mortality once infected with YF than the old world monkeys, suggesting that American YF probably originated from the old world as a result of sailing ships.

The urban form is transmitted between humans by the Aedes aegypti mosquito and thus the potential distribution of urban YF is in any areas where infestation with Aedes aegypti occurs, including Africa, S and N America and Asia. Although the urban vector is present in Asia, yellow fever has never been established there. The majority of reported human YF cases come from Africa (Angola, Cameroon, Gambia, Ghana, Nigeria, Sudan, and Zaire) and S America (Brazil, Bolivia, Columbia, Peru, Ecuador and Venezuela). Both of these continents have jungle yellow fever transmitted in a monkey-mosquito-monkey cycle. In these areas, YF is reintroduced into urban populations from time to time as a result of contact with jungle areas. YF cases occur more frequently at times of the year when there are high temperatures ad high rainfall, conditions which are most conducive to mosquito reproduction.

Once infected, the mosquito vector remains infectious for life. transovarial transmission of Aedes aegypti had been demonstrated and may provide a mechanism for the continuation of the jungle or urban cycle. Once the virus is inoculated into human skin, local replication occurs with eventual spread to the local lymph nodes and viraemia occurs. The target organs are the lymph nodes, liver, spleen, heart, kidney and foregut.

b. Clinical Features

The incubation period varies from 3 to 6 days, following which there is an abrupt onset of chills, fever, and headache. Generalized myalgias and GI complaints (N+V) follows and signs may include facial flushing, red tongue and conjunctival injection. Some patients may experience an asymptomatic infection or a mild undifferentiated febrile illness. After a period of 3 to 4 days, improvement should be seen in most patients. The moderately ill should begin to recover, however, the more severely ill patients with a classical YF course will see a return of fever, bradycardia (Faget's sign), jaundice, and haemorrhagic manifestations. The haemorrhagic manifestations may vary from petechial lesions to epitaxis, bleeding gums, GI haemorrhage (black vomit of YF). 50% of patients with frank YF will develop fatal disease characterized by severe haemorrhagic manifestations, oliguria and hypotension. Frank renal failure is rare. Rarely, other clinical findings such as meningoencephalitis in the absence of other findings have been described.

c. Laboratory Diagnosis

The differential diagnosis of YF include typhoid, leptospirosis, tick-borne relapsing fever, typhus, Q fever, malaria, severe viral hepatitis, Rift valley fever, Crimean-Congo haemorrhagic fever, Lassa, Marburg and Ebola fever. Yellow fever can be diagnosed serologically or by virus isolation. The serological diagnosis can be made by HI, CF and PRN tests. Virus isolation can be attempted from the blood which should be obtained within the first 4 days of illness. A variety of techniques are available for virus isolation, such as intracerebral inoculation of newborn Swiss mice or inoculation into Vero, LLC MK-2, BHK, or arthropod cell lines.

d. Treatment and Prevention

No specific antiviral therapy is available and treatment is supportive. Intensive medical treatment may be required but this is difficult to provide as many epidemics occur in remote areas. Yellow fever is regarded as a quarantinable disease of international public health significance and public health officials should be notified as soon as possible so that vector eradication and mass immunization can be carried out as soon as possible to prevent an epidemic. A live attenuated vaccine known as the 17-D had been available since 1937. The vaccine is regarded as highly effective and generally safe, with mild reactions such as headache, myalgia and low grade fever occurring in 5 to 10% of vaccinees. Vaccination is recommended for residents of endemic areas and should be included in routine vaccination programs. Travelers to endemic areas should also be vaccinated. It is officially recommended that a booster dose should be given every 10 years although this may change in view of recent data on the long persistence of YF antibodies. The contraindications to the use of 17-D vaccine are pregnancy, altered immune states, and hypersensitivity to eggs.

2. Kyasanur Forest Disease

This is a tick borne disease closely related to the tick-borne encephalitis complex and is geographically restricted to Karnataka State in India. Haemorrhagic fever and meningoencephalitis may be seen. The case-fatality rate is 5%.

3. Dengue

Hundreds of thousands of cases of dengue occur every year in endemic and epidemic forms in tropical and subtropical areas of the world. The attack rates during epidemics can reach as high as 50%. Dengue is a prevalent public health problem in SE Asia, the Caribbean, Central America, Northern South America and Africa. (See red coloured areas in map below). In hyperendemic areas, most cases occur in young children as the majority of the population had already been infected with multiple serotypes. In other areas, older children and adults are more likely to be affected. Maximum number of cases occur during the months of the year with the highest rainfall and temperatures, when Aedes aegypti populations are at their highest. A. aegypti mosquitoes deposit their eggs in waterfilled containers and thus reproduction is highest during periods of high rainfall.


4 serologically distinguishable types of dengue are recognized (DEN 1-4). The vector mosquito becomes infected by feeding on a viraemic host. The virus becomes established in the salivary glands of the mosquito from where it can be transmitted to susceptible individuals. Following an incubation period of 2 to 7 days, the virus is disseminated (route unknown), to the organs of the RE system (liver, spleen. bone marrow and lymph nodes). other organs may be involved such as the heart, lungs and GI tract.

a. Clinical Manifestations

The clinical presentation of dengue in children is varied. The disease may be manifested as an undifferentiated febrile illness, an acute respiratory illness, or as a GI illness: atypical presentations which may not be recognized by clinicians as dengue. Older children and adults infected with dengue the first time will display more classical symptoms: sudden onset of fever, severe muscle aches, bone and joint pains, chills, frontal headache and retroorbital pain, altered taste sensation, lymphadenopathy, and a skin rash which appears 3 days after the onset of fever. The rash may be maculopapular, petechial or purpuric and is often preceded by flushing of the skin. Other haemorrhagic manifestations may be seen such as epitaxis, gingival bleeding, ecchymoses, GI bleeding, vaginal bleeding and haematuria. Severe cases of bleeding should not be diagnosed as Dengue haemorrhagic fever (DHF) or Dengue shock syndrome (DSS) unless they meet the criteria below.

DHF or DSS are usually seen in children and usually occurs in 2 stages. The first milder stage resembles that of classical dengue and consists of a fever of acute onset, general malaise, headache, anorexia and vomiting. A cough is frequently present. After 2 to 5 days, the patient's condition rapidly worsens as shock begins to appear. Haemorrhagic manifestations ranging from petechie and bleeding form the gums to GI bleeding may be seen. An enlarged nontender liver is seen in 90% of cases. The WHO recommended the following criteria for the diagnosis of DHF and DSS:

1. Fever
2. Haemorrhagic manifestations including at least a positive tourniquet test.
3. Enlarged liver
4. Shock
5. Thrombocytopenia (<=100,000 ul)
6. Haemoconcentration (HcT increased by =20%)

A diagnosis of DSS is made when frank circulatory failure is seen, and occurs in one third of cases of DHF. DHF has been graded by the WHO on the basis of its severity.

Grade I 

Grade II 

Grade III 

Grade IV

Fever accompanied by non-specific constitutional symptoms, the only haemorrhagic manifestation is a positive tourniquet test 

Spontaneous bleeding in addition to the manifestations of Grade I patients, usually in the form of skin and/or other haemorrhages 

Circulatory failure manifested by rapid and weak pulse, narrowing of pulse pressure (20 mmHg or less) or hypotension, with the presence of cold clammy skin and restlessness 

Profound shock with undetectable blood pressure and pulse

Grade III and Grade IV DHF are also considered as Dengue Shock Syndrome.


b. Immunology

The immunological response to dengue infection depends on the individual's past exposure to flavivirus. The flavivirus group shares cross-reacting antigen(s). Primary infection results in the production of antibodies against the infecting serotype predominantly. Reinfection with another dengue serotype (or other flaviviruses) usually produces a secondary (heterotypic) response characterized by very high titres to all 4 dengue virus serotypes and other flaviviruses, so that serological identification of the infecting agent is quite difficult if not impossible. After a first infection with one dengue serotype, cross-immunity to other serotypes may persists for a few months, but after 6 months, reinfection with another serotype may occur.

c. Pathology

There are 2 theories proposed for the pathogenesis of DHF and DSS: virus virulence and immunopathological mechanisms. The weight of the available evidence supports the immunopathological theory. DHF and DSS occurred most often in patients with a secondary (reinfection) serological response. However, the observation that DHF and DSS occurred in infants with a primary response cast some doubt on this theory until it was demonstrated that preexisting maternal antibody had a similar effect to acquired antibody. The antibody-dependent theory proposes that in the presence of non-neutralizing heterotypic antibody (whether maternally derived or not) to dengue, virus-antibody complexes are formed which are more capable of infecting permissive mononuclear phagocytes than uncomplexed dengue virus.

d. Laboratory Diagnosis

1. Serology - HI, CF and PRN tests are commonly used. The high degree of cross-reactivity between flaviviruses can make the interpretation of serological results very difficult.

2. Virus isolation - this can be accomplished by the intracerebral inoculation of sera from patients into suckling mice. Sera can also be inoculated intrathoracically into Aedes mosquitoes. Head squash preparations are examined for the presence of antigen by the FA technique. Cell cultures such as LLC MK-2 and several mosquito-derived cell lines can be used.

e. Treatment and Prevention

There is no specific antiviral treatment available. Management is supportive and intensive medical management is required for cases of severe DHF and DSS. No vaccine for dengue is available but a tetravalent live-attenuated vaccine has been evaluated in Thailand with favourable results. Scale-up preparation for commercial production of the vaccine is underway and it is anticipated that the vaccine will become available soon and evaluated in large scale clinical trials. To avoid dengue, travelers to endemic areas should avoid mosquito bites. Prevention of dengue in endemic areas depends on mosquito eradication. The population should remove all containers from their premises that may serve as vessels for egg deposition. Vector surveillance is an integral part in control measures to prevent the spread of dengue outbreaks. Regular inspections as part of law enforcement may be used in the control of mosquito vectors. The object of source reduction is to eliminate the breeding grounds in and around the home environment, construction sites, public parks, schools and cemeteries. Illegal dumping of household refuse provide favorable breeding sites for mosquitoes. Long-term control should be based on health education and community participation, supported by legislation and law enforcement. Domestic water supplies should be improved in order to reduce the use of containers for the storage of water.




Orbiviruses are insect-borne viruses primarily of veterinary importance. Orbiviruses contain dsRNA arranged in 10 segments except for the members of the Colorado tick fever serogroup which have 12 segments of dsRNA. They vary in size from 50 to 90nm with 92 capsomers. The capsid is a double-layered protein. The outer coat is diffuse and unstructured while the inner layer is organized in pentameric-hexameric units. Colorado tick fever is caused by a virus belonging to the family of Reoviridae. It is a zoonotic disease of rodents and is transmitted to man via tick bites. It is prevalent in the Rocky Mountains and more western regions of the USA. It is a dengue-like illness albeit with a relatively low incidence. Colorado annually reports 100 to 300 cases but the disease is underreported there and from other western states as well. There is a strong seasonal trend with the majority of cases occurring between February and July. Chipmunks and squirrels serve as amplifying hosts.

Following an incubation period of 3 to 6 days, a high fever of acute onset is seen, along with chills, joint and muscle pains, headache, N+V. A maculopapular rash may be seen in a minority of patients. A more severe clinical picture may be seen in children, who may develop haemorrhagic manifestations including severe GI bleeding and DIC. Aseptic meningitis or encephalitis may be seen. CTF may be diagnosed by virus isolation whereby the patient's blood is inoculated into suckling mice or cell culture lines such as Vero, followed by identification by IF, N or CF tests. More rapid diagnosis can be made by performing IF directly on the blood clots. A IgM tests as well as other serological techniques are available for serological diagnosis. No licensed vaccine for CTF is available nor is it practicable because of the rarity and the benign nature of the disease. Public health education remains the most preventative measure.

Arboviruses Slide Set